Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) α and TGFα/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis

Clinical Cancer Research

Volumn 5, Issue 1, 1999, Pages 35-42

  Nørgaard, Peter ^a,f   Law, Brian ^a,b   Joseph, Heather ^a,b   Page, David L ^c   Shyr, Yu ^c   Mays, Debbie ^b   Pietenpol, Jennifer A ^b   Kohl, Nancy E ^e   Oliff, Alien ^e   Coffey Jr , Robert J ^b,c,d   Poulsen, Hans Skovgaard ^f   Moses, Harold L ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[2 [[2 [(2 AMINO 3 MERCAPTOPROPYL)AMINO] 3 METHYLPENTYL]OXY] 1 OXO 3 PHENYLPROPYL]AMINO] 4 (METHYLSULFONYL)BUTANOIC ACID ISOPROPYL ESTER; 7,12 DIMETHYLBENZ[A]ANTHRACENE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; MITOSIS INHIBITION; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; ONCOGENE NEU; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSGENIC MOUSE; TUMOR BIOPSY; TUMOR REGRESSION;

ALKYL AND ARYL TRANSFERASES; ANIMALS; APOPTOSIS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; G1 PHASE; GROWTH INHIBITORS; MAMMARY NEOPLASMS, EXPERIMENTAL; METHIONINE; MICE; MICE, TRANSGENIC; RECEPTOR, ERBB-2; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 0032900619     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bishop, J. M. Molecular themes in carcinogenesis. Cell, 64: 235-248, 1991.
2. Hunter, T. Oncoprotein networks. Cell, 88: 333-346, 1997.
3. Dickson, R. B., Johnson, M. D., Mozeena, B., Shi, E., Kurebayashi, J., Ziff, B., Martinez-Lacaci, I., Amundadottir, L. T., and Lippman, M. E. Growth factors in breast cancer: mitogenesis to transformation. J. Steroid Biochem. Mol. Biol., 43: 69-78, 1992.
4. Normanno, N., and Ciardiello, F. EGF-related peptides in the pathophysiology of the mammary gland. J. Mamm. Gland Biol. Neopl., 2: 143-151, 1997.
5. Lowy, D. R., and Willumsen, B. M. Function and regulation of Ras. Annu. Rev. Biochem., 62: 851-891, 1993.
6. Bos, J. L. Ras oncogenes in human cancer: a review. Cancer Res., 49: 4682-4689, 1989.
7. Sivaraman, V. S., Wang, H., Nuovo, G. J., and Malbon, C. C. Hyperexpression of mitogen-activated protein kinase in human breast cancer. J. Clin. Invest., 99: 1478-1483, 1997.
8. Maltese, W. A. Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J., 4: 3319-3328, 1990.
9. Gibbs, J. B., Oliff, A., and Kohl, N. E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell, 77: 175-178, 1994.
10. Kohl, N. E., Mosser, S. D., deSolms, J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Oliff, A., and Gibbs, J. B. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science (Washington DC), 260: 1934-1937, 1993.
11. James, G. L., Goldstein, J. L., Brown, M. S., Rawson, T. E., Somers, T. C., McDonell, R. S., Crowley, C. W., Lucas, B. K., Levison, A. D., and Marsters, J. C., Jr. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science (Washington DC), 260: 1937-1942, 1993.
12. Kohl, N. E., Omer, C. A., Conner, M. W., Anthony, N. J., Davide, J. P., DeSolms, S. J., Giuliani, E. A., Gomez, R. P., Graham, S. L., Hamilton, K., Handt, L. K., Hartman, G. D., Koblan, K. S., Kral, A. M., Miller, P. J., Mosser, S. D., O'Neill, T. J., Rands, E., Schaber, M. D., Gibbs, J. B., and Oliff, A. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med., 1: 792-797, 1995.
13. Barrington, R. E., Subler, M. A., Rands, E., Omer, C. A., Miller, P. J., Hundley, J. E., Koester, S. K., Troyer, D. A., Bears, D. J., Conner, M. W., Gibbs, J. B., Hamilton, K., Koblan, K. S., Mosser, S. D., O'Neill, T. J., Schaber, M. D., Senderak, E. T., Windle, J. J., Oliff, A., and Kohi, N. E. A famesyltranferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell. Biol., 18: 85-92, 1998.
14. Mangues, R., Corral, T., Kohl, N. E., Symmans, W. F., Lu, S., Malumbres, M., Gibs, J. B., Oliff, A., and Pellicer, A. Antitumor effect of a famesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res., 58: 1253-1259, 1998.
15. Sepp-Lorenzino, L., Ma, Z., Rands, E., Kohl, N. E., Gibbs, J. B., Oliff, A., and Rosen, N. A peptidomimetic inhibitor of famesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res., 55: 5302-5309, 1995.
16. Moasser, M. M., Sepp-Lorenzino, L., Kohl, N. E., Oliff, A., Balog, A., Su, D-S., Danishefsky, S. J., and Rosen, N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA, 95: 1369-1374, 1998.
17. Matsui, Y., Halter, S. A., Holt, J. T., Hogan, B. L. M., and Coffey, R. J. Development of mammary hyperplasia and neoplasia in MMTV-TGFα transgenic mice. Cell, 61: 1147-1155, 1990.
18. Jhappan, C., Stahle, C., Harkins, R., Fausto, R., Smith, G., and Merlino, G. TGFα overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell, 61: 1137-1146, 1990.
19. Sandgren, E. P., Lutteke, N. C., Palmiter, R. D., Brinster, R. L., and Lee, D. Overexpression of TGFα in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell, 61: 1121-1135, 1990.
20. Guy, G. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., and Muller, W. J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA, 89: 10578-10582, 1992.
21. Halter, S. A., Dempsey, P. J., Matsui, Y., Stokes, M. K., Graves-Deal, R., Hogan, B. L. M., and Coffey, R. J. Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-a. Am. J. Pathol., 140: 1131-1146, 1992.
22. Coffey, R. J., Meise, K. S., Matsui, Y., Hogan, B. L. M., Dempsey, P. J., and Halter, S. A. Acceleration of mammary neoplasia in transforming growth factor a transgenic mice by 7,12-dimethylbenzanthracene. Cancer Res., 54: 1678-1683, 1994.
23. Muller, W. J., Arteaga, C. L., Muthuswamy, S. K., Siegel, P. M., Webster, M. A., Cardiff, R. D., Meise, K. S., Li, F., Halter, S. A., and Coffey, R. J. Synergistic interaction of the neu proto-oncogene product and transforming growth factor a in the mammary epithelium of transgenic mice. Mol. Cell. Biol., 16: 5726-5736, 1996.
24. Dexter, D. L., Diamond, M., Creveling, J., and Chen, S-F. Chemotherapy of mammary carcinomas arising in ras transgenic mice. Invest. New Drugs, 11: 161-168, 1993.
25. 2 experimental units. Biometrics, 24: 61-73, 1968.
26. Ausubel, F. M., et al. (eds.), Short Protocols in Molecular Biology. New York: John Wiley & Sons; Inc., 1992.
27. Kumar, R., Medina, D., and Sukumar, S. Activation of H-ras oncogenes in preneoplastic mouse mammary tissues. Oncogene, 5: 1271-1277, 1990.
28. Wood, W. I., Gitschier, J., Lasky, L. A., and Lawn, R. M. Base composition-independent hybridization in tetramethylammonium chloride: a method for oligonucleotide screening of highly complex gene libraries. Proc. Natl. Acad. Sci. USA, 82: 1585-1588, 1985.
29. Balmain, A., and Brown, K. Oncogene activation in chemical carcinogenesis. Adv. Cancer Res., 57: 147-182, 1988.
30. Kohl, N. E., Wilson, F. R., Mosser, S. D., Giuliani, E. A., DeSolms, S. J., Conner, M. W., Anthony, N. J., Holtz, W. J., Gomez, R. P., Lee, T-J., Smith, R. L., Graham, S. L., Hartman, G. D., Gibbs, J. B., and Oliff, A. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. USA, 91: 9141-9145, 1994.
31. Nagasu, T., Yoshimatsu, K., Rowell, C., Lewis, M. D., and Garcia, A. M. Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res., 55: 5310-5314, 1995.
32. Sun, J., Qian, Y., Hamilton, A. D., and Sebti, S. M. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-ras mutation and p53 deletion. Cancer Res., 55: 4243-4247, 1995.
33. Yonemoto, M., Satoh, T., Arakwa, H., Suzuki-Takahashi, I., Monden, Y., Rodera, T., Tanaka, K., Aoyama, T., Iwasawa, Y., Kamei, T., Nishimura, S., and Tomimoto, K. J104.871, a novel farnesyltransferase inhibitor, blocks ras farnesylation in vivo in a farnesyl pyrophosphate competitive manner. Mol. Pharmacol., 54: 1-7, 1998.
34. Hung, W-C., and Chaung, L. Y. The farnesyltranferase inhibitor, FPT inhibitor III, upregulates Bax and Bcl-xs expression and induces apoptosis in human ovarian cancer cells. Int. J. Oncol., 12: 137-140, 1998.
35. Bernhard, E. J., Kao, G., Cox, A. D., Sebti, S. M., Hamilton, A. D., Muschel, R. J., and McKenna, W. G. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res., 56: 1727-1730, 1996.
36. Lebowitz, P. F., Sakamuro, D., and Prendergast, G. C. Famesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment. Cancer Res., 57: 708-713, 1997.
37. Lebowitz, P. F., Davide, J. P., and Prendergast, G. C. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol. Cell. Biol., 15: 6613-6622, 1995.